asa glp 1 recommendations glp-1 The 2023 ASA position on GLP-1 receptor agonists has been overturned by three 2025 consensus statements. Continue the drug. A very important and practice-changing

She was incredibly knowledgeable, supportive, and attentive throughout the entire experience

The role of pediatricians as innovators in pediatric nutrition

Ipamorelin is a ghrelin receptor agonist (GHS-R1a) that stimulates GH secretion through a mechanistically separate pathway

Lipo C injections are safe when administered by a qualified healthcare professional

Retinol has more evidence for visible wrinkle reduction

GIP receptor activation complements these effects by promoting insulin secretion, while potentially improving insulin sensitivity in peripheral tissues and influencing lipid metabolism and energy expenditure, though these additional effects have more limited human data